A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.

Giles, Francis;Verstovsek, Srdan;Faderl, Stefan;Vey, Norbert;Feldman, Eric;et.al.
(2006) Leukemia Research : clinical and laboratory studies — Vol. 30, n° 12, p. 1591-1595 (2006)

Files

No attached file found for this publication.

Details

Authors
  • Giles, Francis
    Author
  • Verstovsek, Srdan
    Author
  • Faderl, Stefan
    Author
  • Vey, Norbert
    Author
  • Ferrant, AugustinUCLouvain
    Author
  • Feldman, Eric
    Author
Show more
Abstract
Cloretazine (VNP40101M) is a sulfonylhydrazine alkylating agent with significant anti-leukemia activity. A multicenter phase II study of cloretazine was conducted in patients with first relapse of acute myeloid leukemia (AML) following an initial complete remission (CR) of less than 12 months. Cloretazine was given as a single intravenous infusion at a dose of 600 mg/m(2). Fifty-three patients (median age 62 years (18-84), 41 of 44 (93%) evaluable with intermediate or high risk cytogenetics, 32 (60%) with initial CR durations < or =6 months) were treated on study. Two patients (4%) achieved a second CR. Five (9%) patients died within 30 days of receiving cloretazine therapy. Median overall survival (2.3 months) in the study cohort was directly comparable to that of 233 matched patients treated with other single agents. The study cloretazine regimen had minimal activity in a very high risk subset of patients with relapsed AML.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Giles, F., Verstovsek, S., Faderl, S., Vey, N., Karp, J., Roboz, G., Khan, K. D., Cooper, M., Bilgrami, S. F. A., Ferrant, A., Daenen, S., Karsten, V., Cahill, A., Albitar, M., Kantarjian, H., O’Brien, S., & Feldman, E. (2006). A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia Research : clinical and laboratory studies, 30(12), 1591-1595. https://doi.org/10.1016/j.leukres.2006.02.019 (Original work published 2006)